Pharmaceutical Research and Manufacturers of America and drug maker Johnson & Johnson each filed a friend of the court brief in June backing Novartis and United Therapeutics in those two companies’ appeals of a federal district judge’s November decision that
…
U.S. Senate Democrats’ revamped drug pricing legislation would lower the federal deficit by $287 billion over 10 years, the nonpartisan Congressional Budget Office said late last week.
Last November, CBO estimated that drug pricing language in the House-passed Build Back
…
Hospitals enrolled in the 340B program will have to recertify their eligibility for reduced 340B drug pricing this year between Aug. 24 and Sept. 19, the U.S. Health Resources and Services Administration says.
340B covered entities must annually recertify their
…
If Congress votes to gives Medicare the power to negotiate some drug prices, drug manufacturers would not have to provide price concessions that exceed the lower of a drug’s 340B price or the Medicare negotiated price, according to a summary
…
The U.S. Office of Pharmacy Affairs (OPA), the department within the U.S Health and Resources Administration that oversees the 340B program, would receive a $2 million increase in funding under a bill that passed through a major House committee last
…
The U.S. Department of Health and Human Services should swiftly use its existing statutory authority—including forcing drug patent owners to license their products to others—to lower drug prices, 100 Democratic members of Congress urged HHS Secretary Xavier Becerra late last
…
Five groups that represent 340B hospitals have filed briefs in two federal appeals courts backing the federal government in its fight to force drug manufacturers Eli Lilly and AstraZeneca to end restrictions on 340B drug discounts when covered entities use
…
Drug manufacturers’ decisions to impose conditions on 340B pricing when covered entities use contract pharmacies “need to be addressed moving forward,” U.S. Rep. Debbie Dingell (D-Mich.) said last week during an Energy & Commerce (E&C) health subcommittee hearing last week.
…
For the fourth time this year, drug manufacturer Lilly has announced refunds for overcharges on 340B-purchased drugs during 2019.
The U.S. Health Resources and Services Administration (HRSA) posted the notice, dated May 27, on the Office of Pharmacy Affairs website
…
Drug manufacturers Novo Nordisk and Sanofi last month urged a federal appeals court to reverse a district judge’s ruling that the companies’ conditions on 340B pricing when providers use multiple contract pharmacies violate the 340B statute.
Meanwhile, the federal government
…
×
*Sign up for news summaries and alerts from 340B Report